Drug Delivery to the Kidneys and the Bladder with the Low Molecular Weight Protein Lysozyme
Robbert J. Kok(Utrecht University), Dirk Meijer(University of Groningen), Dick de Zeeuw(University Medical Center Groningen), Frits Moolenaar(University of Groningen), Marijke Haas(University of Groningen)
Cited by 25
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)
|Kidney International|2005|3.9k
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
|Data Archiving and Networked Services (DANS)|2003|2.5k